drugset / Trial / NCT05096390
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-10
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |